Literature DB >> 4564560

Infection-immunity in tularemia: specificity of cellular immunity.

J L Claflin, C L Larson.   

Abstract

The relationship between hypersensitivity and cellular resistance to infection with facultative intracellular parasites was studied in mice by using infection-immunity in tularemia as a model system. Delayed hypersensitivity to antigenic fractions of Francisella tularensis was first detected 6 to 7 days after immunization with viable F. tularensis vaccine, at which time immunity against challenge infection developed. Both immunity and delayed-type sensitivity reached maximal levels by 9 to 10 days. Immediate hypersensitivity occurred after immunization with both viable and nonviable tularemia vaccines but could not be correlated with resistance since nonviable antigens were not protective. Attempts to relate resistance to F. tularensis with nonspecific immunity factors were unsuccessful. Immunization of mice with BCG vaccine stimulated protection against infection with F. novicida and Salmonella typhimurium but provided no protection against infection with F. tularensis. Moreover, viable tularemia vaccine, while inducing marked protection against challenge with specific organisms, afforded no protection against infection with S. typhimurium or S. enteritidis. It is concluded that cellular immunity in tularemia involves an immunologically specific component.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4564560      PMCID: PMC422367          DOI: 10.1128/iai.5.3.311-318.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Delayed hypersensitivity and arthus reactivity in relation to host resistance in salmonella-infected mice.

Authors:  F M Collins; G B Mackaness
Journal:  J Immunol       Date:  1968-11       Impact factor: 5.422

Review 2.  Cellular hypersensitivity and cellular immunity in the pathogensis of tuberculosis: specificity, systemic and local nature, and associated macrophage enzymes.

Authors:  A M Dannenberg
Journal:  Bacteriol Rev       Date:  1968-06

Review 3.  Cellular immunity.

Authors:  G B Mackaness; R V Blanden
Journal:  Prog Allergy       Date:  1967

4.  Increased antibacterial resistance and immunodepression during graft-versus-host reactions in mice.

Authors:  R V Blanden
Journal:  Transplantation       Date:  1969-06       Impact factor: 4.939

5.  The effect of anti-lymphocyte globulin on cell-mediated reistance to infection.

Authors:  G B Mackaness; W C Hill
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

6.  Studies on the mechanisms of resistance to phylogenetically diverse intracellular organisms.

Authors:  J Ruskin; J McIntosh; J S Remington
Journal:  J Immunol       Date:  1969-08       Impact factor: 5.422

7.  Recall of immunity in mice vaccinated with Salmonella enteritidis or Salmonella typhimurium.

Authors:  F M Collins
Journal:  J Bacteriol       Date:  1968-06       Impact factor: 3.490

8.  Immunogenicity of cell walls from various mycobacteria against airborne tuberculosis in mice.

Authors:  W Brehmer; R L Anacker; E Ribi
Journal:  J Bacteriol       Date:  1968-06       Impact factor: 3.490

9.  In vitro interactions between rabbit alveolar macrophages and Pasteurella tularensis.

Authors:  J E Nutter; Q N Myrvik
Journal:  J Bacteriol       Date:  1966-09       Impact factor: 3.490

10.  The influence of immunologically committed lymphoid cells on macrophage activity in vivo.

Authors:  G B Mackaness
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  24 in total

Review 1.  Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man.

Authors:  A Tärnvik; M Eriksson; G Sandström; A Sjöstedt
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

2.  Modulation of delayed-type hypersensitivity and cellular immunity to microbial vaccines: effects of cyclophosphamide on the immune response to tularemia vaccine.

Authors:  M S Ascher; D Parker; J L Turk
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

3.  Interleukin 2 and gamma interferon production, interleukin 2 receptor expression, and DNA synthesis induced by tularemia antigen in vitro after natural infection or vaccination.

Authors:  R Karttunen; G Andersson; H P Ekre; K Juutinen; H M Surcel; H Syrjälä; E Herva
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

4.  Protein heterogeneity of Francisella tularensis: detection of proteins with antigenic determinants.

Authors:  J Stulik; J Cerna; H Kovarová; A Macela
Journal:  Folia Microbiol (Praha)       Date:  1989       Impact factor: 2.099

5.  Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.

Authors:  Rebecca V Anderson; Deborah D Crane; Catharine M Bosio
Journal:  Vaccine       Date:  2010-08-03       Impact factor: 3.641

6.  Stimulation of subpopulations of human lymphocytes by a vaccine strain of Francisella tularensis.

Authors:  A Tärnvik; S E Holm
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

7.  Herpesvirus hominis type 2 infections in rabbits: effect of prior immunization with attenuated Mycobacterium bovis (BCG) cells.

Authors:  C L Larson; R N Ushijima; R Karim; M B Baker; R E Baker
Journal:  Infect Immun       Date:  1972-10       Impact factor: 3.441

8.  Humoral immunity against Francisella tularensis after natural infection.

Authors:  P Koskela; A Salminen
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

9.  In vitro correlates of delayed hypersensitivity in man: ambiguity of polymorphonuclear neutrophils as indicator cells in leukocyte migration test.

Authors:  G Senyk; W K Hadley
Journal:  Infect Immun       Date:  1973-09       Impact factor: 3.441

10.  Cell-mediated and humoral immunity induced by a live Francisella tularensis vaccine.

Authors:  P Koskela; E Herva
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.